View PDF
Exonhit enters into Research Agreement with. Pfizer to identify Alzheimer's disease biomarkers. Monday October 10
05_EXT_06 Biomerieux final
bioMérieux and ExonHit Therapeutics Extend their Strategic Collaboration. Development of blood diagnostics for the early detection of cancers.
MacroGenics ExonHit Therapeutics
ExonHit. Therapeutics is exploiting its understanding of mRNA splicing to enable it to identify promising diagnostic and therapeutic tar-.
AviaraDx Acquisition
11 sept. 2008 8 biomarkers. Licensing/theranostics: Merck assay... NucliSENS EasyQ®. Mixed units: Shanghai
Etazolate a neuroprotective drug linking GABAA
E-mail: laurent.desire@exonhit.com. Abbreviations used: Ab beta amyloid; ADAM
62 Validation dune signature transcriptomique (EHT Dx14) sur des
de la technologie de biopuces d'ExonHit SA [3] et ayant la capacité de différen- cier une tumeur mammaire maligne de lésions bénignes
RESOURCES PEOPLE
ExonHit Therapeutics (Paris) has announced the appointments of Florence. Abrahamian as financial director Jim Liddy as vice president
Blood Transcriptomic Biomarkers of Alzheimers Disease Patients
?Correspondence to: Laurent Désiré Exonhit SA
diaporama-olivier-hanon.pdf
Exonhit. X. X. X. Page 3. Hypertension artérielle. Page 4. Lancet 2010; 375: 895–905. 4 études. UK-TIA=2 435. ESPS1=2 500. Dutch TIA n=3 150.
View PDF
4 avr. 2011 http://www.decode.com/news/news.php?story=156 October 102011 Exonhit enters into. Research Agreement with Pfizer to!identify Alzheimer's ...
